Regeneron (REGN): Is This Biotech Giant a Buy Now?
AI-powered insights updated on 8/29/2025.
AI Signal: BUY
Regeneron (REGN) exhibits strong momentum with positive Phase 3 trial results and analyst upgrades outweighing minor setbacks, pointing to potential near-term gains. While facing some manufacturing headwinds, underlying fundamentals remain solid, supporting a bullish outlook.
Phase 3 Trial Results
Positive results for Cemdisiran in Generalized Myasthenia Gravis
Analyst Upgrade
Bernstein raised price target to $781
Dupixent Sales
Strong growth exceeding $4.3 billion quarterly
Full Analysis Breakdown
Expand the sections below for a detailed look at our analysis.
Go Beyond the Analysis
Get real-time insights, compare stocks, and chat with our AI analyst on the interactive dashboard.
Disclaimer
The information provided on this page is for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other sort of advice and you should not treat any of the page's content as such. ProfitScout does not recommend that any cryptocurrency should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions.